ATX-101 Abdominoplasty

Phase 1

Completed

• Conditions: Characteristics of Subcutaneous Fat
• Interventions: Drug: ATX-101

• Registration Number: NCT00835952
• Lead Sponsor: Kythera Biopharmaceuticals

Brief Summary

Histopathological study of abdominal fat excised from subjects undergoing abdominoplasty

Detailed Description

Not available

Study Timeline

• Study Start: 2008-11
• Study First Submitted: 2009-02-03
• Study First Submitted QC: 2009-02-03
• Study First Posted: 2009-02-04
• Primary Completion: 2009-03
• Study Completion: 2009-04
• Status Verified: 2010-01
• Last Update Submitted: 2010-01-25
• Last Update Posted: 2010-01-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 14

Inclusion Criteria

• Healthy subjects undergoing planned abdominoplasty

Exclusion Criteria

• History of interventions in the abdominal area

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
ATX-101	ATX-101	-

Primary Outcome Measures

Name	Time	Method
Adverse events, laboratory test results, physical examinations	1 - 28 days

Secondary Outcome Measures

Name	Time	Method
Histopathology	1 - 28 Days